SAB Scientific Advisory Board

Professor David S. Perlin, PhD; Chairman of Scientific Board

David S. Perlin Ph.D. has been the Scientific Director of Public Health Research Institute since 1992, and lately President. He has helped advance PHRI's research agenda including the Institute's emergence of as one of the foremost tuberculosis research organizations in the world and the development of the International Center for
Public Health as a specialized center for infectious diseases research.

Dr. Perlin's lab studies the molecular basis for clinical resistance to antifungal drugs and helps develop rapid diagnostic approaches for fungal pathogens, agents of bioterrorism, and new disease agents like the SARS coronavirus. Since the anthrax outbreak in October 2001, Dr. Perlin has been widely outspoken about the public health response to the crisis and the need for research and improved infrastructure.

He has been a regular commentator on radio and television, lectures on biodefense issues, has published
numerous letters in the New York Times and other media outlets, and wrote one of the primary scientific critiques
of the outbreak for the U.S. Senate. Dr. Perlin is a member of the Executive Committee of the Northeast Biodefense Center, a research-driven consortium of 30+ academic and government institutions in New York , New Jersey
and Connecticut. He regularly serves on NIH review panels, is on the editorial board of a number of biomedical research journals, and is a member of Senator Jon Corzine's New Jersey Healthcare Taskforce.

Dr. Perlin obtained an A.B degree from Brandeis University (1976) and a Ph.D. from Cornell University (1980).
He pursued postdoctoral studies in the Department of Human Genetics at the Yale University School of Medicine (1980-1982) and in the Department of Biochemistry at the University of Rochester School of Medicine (1983-1985). He joined the Public Health Research Institute in fall 1985. Information about Dr. Perlin's research program is
found in the Research Section of the PHRI web site. Dr. Perlin is a member of the PHRI Executive and Strategic Planning Committees.

Joseph R Flicek; Intellectual Property Advisor

Mr. Flicek is a Managing Director of Amphion Innovations in their New York Office.  Amphion's business is the formation, financing, management and development of life science and technology companies. He specializes
in taking these new technologies and under-performing assets and leveraging and enhancing their intellectual property and business assets into profitable company building opportunities. Amphion Portfolio Companies are
broad-based, proprietary, platform technologies in the areas of pharmacogenomics, nutriceuticals, diagnostics, medical products and related fields, leveraging advances in semiconductors, RFID technologies and life science
IT technologies.

He currently serves on the boards of FireStar Software, Inc. and M2M Inc, who are Amphion partner companies.
Mr. Flicek created and established the New Ventures group of the Science & Technology Ventures Office at
Columbia University in 1996.  Under his leadership Columbia participated in the formation of over 30 new
University spin-outs, four of which are publicly traded. Mr. Flicek is an adjunct faculty member of Columbia
University's Graduate Business School in Entrepreneurship and assists faculty and students in startup businesses through entrepreneurship programs.

Paul Bowyer PhD

Dr Bowyer is a Senior Scientist and Lecturer in Molecular Biology at the University of Manchester. He earned
his first degree in Biochemistry at the University of Bath in 1985 and obtained a PhD in fungal molecular biology
from the University of Sheffield in 1991.

Dr Bowyer began work with fungi in 1985 during his PhD on the metabolism and molecular genetics of Aspergillus nidulans with Professor Geoff Turner. Since then he has worked in a variety of laboratories including the Sainsbury Laboratory in Norwich, UK and at the University of Bristol (IACR Long Ashton) where he has expanded his interest in the molecular biology of fungal pathogens. He has published some pivotal work in the area, including papers in Science and Nature.

His current research interests are in molecular diagnostics and the biology of allergic or invasive diseases caused
by fungi. In particular he is interested in development of novel molecular diagnostic tools and discovery of genes involved in pathogenicity or allergenicity. He collaborates closely with colleagues in the Faculties of Medicine
and Life Sciences in the University of Manchester including Profs. David Denning and Terri Attwood, Drs William Hope and Peter Warn. He is the author of several patent applications.